Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,491 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Thorax Clear all

Conditions: Pleural Effusions
Interventions: Not listed
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Neoplasms
Interventions: GSK3326595, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • New York, New York + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Interventions: EP2101; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Albany, New York + 5 more

Conditions: Non-Small Cell Lung Cancer
Interventions: MGCD265; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 47
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more

Conditions: Lung Cancer
Interventions: BIBW 2992; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Docetaxel; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Irvine, California • Los Alamitos, California • Orange, California + 3 more

Conditions: Advanced Cancers
Interventions: Atorvastatin, Fish Oil Supplement, Placebo; Drug · Dietary Supplement · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Genetic Predisposition, Paraganglioma, Pheochromocytoma, ALS, Parkinson Disease, Polyneuropathies, Frontotemporal Dementia, Alzheimer Disease, Cardiomyopathy Non-ischemic, Thoracic Aortic Aneurysm
Interventions: Behavioral nudge; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma
Interventions: Pembrolizumab, Laboratory Biomarker Analysis, Pharmacogenomic Study; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer
Interventions: adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-Small-Cell Lung Cancer
Interventions: pemetrexed, cisplatin, carboplatin, radiation therapy; Drug · Radiation
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 9
States / cities: Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more

Conditions: Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions: HWK-007; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more

Conditions: Non-small Cell Lung Cancer
Interventions: cisplatin, Docetaxel, Pegfilgrastim; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer
Interventions: conventional surgery, radiofrequency ablation; Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer of the Lung, Abdominal Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 86 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Non-small Cell Lung Cancer
Interventions: cediranib maleate, laboratory biomarker analysis, pharmacogenomic studies; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cytology specimen collection procedure, laboratory biomarker analysis; Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 11
States / cities: Bay City, Michigan • Bloomfield Hills, Michigan • Clarkston, Michigan + 8 more

Conditions: Small Cell Lung Cancer
Interventions: AT-101, topotecan; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: BAY2862789; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Celebration, Florida • Detroit, Michigan • San Antonio, Texas

Conditions: Solid Tumors, Lung Cancer
Interventions: BKM120, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: epoetin alfa, placebo; Biological · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 20
States / cities: Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 26
States / cities: Los Angeles, California • Sebastopol, California • Stamford, Connecticut + 23 more

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Search by objective public record fields.

A Study to Establish the Diagnostic Value of the EPISEEK-MPE Liquid Biopsy Assay to Identify Cancer in Pleural Effusion Samples.

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

Investigating the Improvement in 4D CT Images Using AV Biofeedback

AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)